Patents by Inventor Johan Fransson

Johan Fransson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST THE POLIOVIRUS RECEPTOR (PVR) AND USES THEREOF
    Publication number: 20260152568
    Abstract: The present application provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers. The present application also provides a method of treating a cancer in an individual afflicted with a cancer comprising administering to the individual a therapeutically effective amount of chimeric antigen receptor (CAR) NK or T cells.
    Type: Application
    Filed: January 15, 2026
    Publication date: June 4, 2026
    Applicant: NECTIN THERAPEUTICS LTD.
    Inventors: Philipp ALBERTS, Arif JETHA, Johan FRANSSON, Yazen JMEIAN, Joanne HULME, Pinchas TSUKERMAN
  • Antibodies against the poliovirus receptor (PVR) and uses thereof
    Patent number: 12570757
    Abstract: The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: March 10, 2026
    Assignee: NECTIN THERAPEUTICS LTD.
    Inventors: Philipp Alberts, Arif Jetha, Johan Fransson, Yazen Jmeian, Joanne Hulme, Pinchas Tsukerman
  • Anti-CD30L antibodies and uses thereof
    Patent number: 12516126
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: November 15, 2023
    Date of Patent: January 6, 2026
    Assignees: Prometheus Biosciences, Inc., Dr. Falk Pharma GMBH
    Inventors: Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
  • FLT3 agonist antibodies and uses thereof
    Patent number: 12473365
    Abstract: Described herein are anti-FLT3 agonistic antibodies. Such agonistic antibodies are useful for the expansion of dendritic cells and the treatment of cancer.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 18, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Arif Jetha, Phil Gobeil, Melissa Beilschmidt, Dorothea Maetzel, Johan Fransson
  • ANTI-CD30L ANTIBODIES, FORMULATIONS THEREFOR, AND USES THEREOF
    Publication number: 20250340660
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: July 24, 2023
    Publication date: November 6, 2025
    Applicants: PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBH
    Inventors: Johan Fransson, Brian Connolly, Cindy T. Dickerson, Jessie-Farah Fecteau, Mark Renshaw, Olivier Laurent, Burton Barnett, Ernesto J. Munoz
  • ANTI-CD30L ANTIBODIES AND USES THEREOF
    Publication number: 20240254246
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 16, 2022
    Publication date: August 1, 2024
    Inventors: Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
  • Human Anti-CD27 Antibodies
    Publication number: 20240141055
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: June 29, 2023
    Publication date: May 2, 2024
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ANTI-CD30L ANTIBODIES AND USES THEREOF
    Publication number: 20240092923
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: November 15, 2023
    Publication date: March 21, 2024
    Inventors: Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
  • Anti-CD30L antibodies and uses thereof
    Patent number: 11866505
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 9, 2024
    Assignees: PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBH
    Inventors: Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
  • Neutralizing human anti-CD27 antibodies
    Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ANTI-CD30L ANTIBODIES AND USES THEREOF
    Publication number: 20230060624
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: August 26, 2022
    Publication date: March 2, 2023
    Inventors: Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20230050773
    Abstract: Disclosed herein are antibodies that specifically bind and inhibit the action of the IL-6 family member LIF that are useful in the treatment of cancer. Also disclosed herein are uses of said antibodies for the treatment of cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 16, 2023
    Inventors: Arif JETHA, Johan FRANSSON
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20230042095
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: June 23, 2022
    Publication date: February 9, 2023
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • METHODS OF TREATING CANCER BY THE USE OF PD-1 AXIS INHIBITORS AND ANTI-PERIOSTIN ANTIBODIES
    Publication number: 20230030597
    Abstract: Described herein are methods of treating cancer comprising administering to the individual (a) a PD-1 axis inhibitor; and (b) an inhibitor of periostin.
    Type: Application
    Filed: August 27, 2020
    Publication date: February 2, 2023
    Inventors: Arif JETHA, Johan FRANSSON, AJ Robert MCGRAY, Joanne HULME
  • ANTIBODIES AGAINST THE POLIOVIRUS RECEPTOR (PVR) AND USES THEREOF
    Publication number: 20220372161
    Abstract: The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.
    Type: Application
    Filed: October 7, 2020
    Publication date: November 24, 2022
    Applicant: NECTIN THERAPEUTICS LTD.
    Inventors: Philipp ALBERTS, Arif JETHA, Johan FRANSSON, Yazen JMEIAN, Joanne HULME, Pinchas TSUKERMAN
  • Nucleic acids encoding anti-CD154 antibodies
    Patent number: 11421037
    Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 23, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
  • Antibodies against LIF and uses thereof
    Patent number: 11390670
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: July 19, 2022
    Assignees: MEDIMMUNE LIMITED, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGIC, FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Johan Fransson, Jean-Philippe Julien, Swetha Raman
  • FLT3 AGONIST ANTIBODIES AND USES THEREOF
    Publication number: 20220025055
    Abstract: Described herein are anti-FLT3 agonistic antibodies. Such agonistic antibodies are useful for the expansion of dendritic cells and the treatment of cancer.
    Type: Application
    Filed: December 17, 2019
    Publication date: January 27, 2022
    Inventors: Arif JETHA, Phil GOBEIL, Melissa BEILSCHMIDT, Dorothea MAETZEL, Johan FRANSSON
  • ANTI-PERIOSTIN ANTIBODIES AND USES THEREOF
    Publication number: 20220010003
    Abstract: Described herein are antibodies that block the function of periostin. Also described herein are their uses in treating cancer and modifying tumor immune properties.
    Type: Application
    Filed: December 13, 2019
    Publication date: January 13, 2022
    Inventors: Arif JETHA, Johan FRANSSON, AJ Robert MCGRAY, Joanne HULME
  • METHODS OF QUANTIFYING LIF AND USES THEREOF
    Publication number: 20210190798
    Abstract: Described herein are assays useful for the quantitation of total LIF from biological samples.
    Type: Application
    Filed: June 17, 2019
    Publication date: June 24, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Peter Edward BAYLISS, Patricia Anne GIBLIN, Johan FRANSSON, Arif JETHA